Member of the Association of American Physicians
Prostate cancer, Cancer research, Internal medicine, Oncology and Pathology are his primary areas of study. The study incorporates disciplines such as Prostate and Antibody in addition to Prostate cancer. His studies deal with areas such as Receptor, Bioinformatics, Circulating tumor cell and Somatic evolution in cancer as well as Cancer research.
Internal medicine is often connected to Endocrinology in his work. The Oncology study combines topics in areas such as Abiraterone acetate, Clinical trial and Denosumab. His Pathology research includes elements of Metastasis and Monoclonal Antibody J591.
David M. Nanus mainly focuses on Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer. David M. Nanus combines subjects such as Docetaxel, Prostate and Circulating tumor cell with his study of Prostate cancer. His Endocrinology research extends to the thematically linked field of Internal medicine.
His research in Oncology intersects with topics in Gemcitabine, Clinical trial, Enzalutamide and Cohort. His Cancer research study incorporates themes from Cell, Pathology, Antibody, Monoclonal antibody and Retinoic acid. The various areas that he examines in his Cancer study include Immunology and PTEN.
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer. His Prostate cancer research is multidisciplinary, relying on both Chemotherapy, Circulating tumor cell and Dose escalation. His Oncology research is multidisciplinary, incorporating elements of Docetaxel, Enzalutamide, Radionuclide therapy and Cohort.
His Cancer research research is multidisciplinary, incorporating perspectives in Prostate, Glutamate carboxypeptidase II, Downregulation and upregulation, Antibody and Targeted radionuclide therapy. His Prostate research includes themes of Biopsy and DNA methylation. His study looks at the relationship between Cancer and topics such as Disease, which overlap with Diabetes mellitus.
His main research concerns Prostate cancer, Cancer research, Oncology, Internal medicine and Circulating tumor cell. David M. Nanus specializes in Prostate cancer, namely Androgen receptor. His research integrates issues of Dose escalation, Phenotype, Epigenomics, Castration resistant and Receptor in his study of Cancer research.
His Oncology study combines topics in areas such as MEDLINE, Enzalutamide, Carcinoma, Docetaxel and Prospective cohort study. When carried out as part of a general Internal medicine research project, his work on Hematology and Outpatient clinic is frequently linked to work in Restructuring, therefore connecting diverse disciplines of study. His study in Biopsy is interdisciplinary in nature, drawing from both Cancer, Prostate and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
Robert J. Motzer;Neil H. Bander;David M. Nanus.
The New England Journal of Medicine (1996)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran;Himisha Beltran;Davide Prandi;Juan Miguel Mosquera;Juan Miguel Mosquera;Matteo Benelli.
Nature Medicine (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano.
Journal of Clinical Oncology (2016)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran;David S. Rickman;Kyung Park;Sung Suk Chae.
Cancer Discovery (2011)
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
Neil H. Bander;Matthew Ivan Milowsky;David M. Nanus;Lale Kostakoglu.
Journal of Clinical Oncology (2005)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran;Roman Yelensky;Garrett M. Frampton;Kyung Park.
European Urology (2013)
Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial
Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn.
Journal of Clinical Oncology (2007)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S Darshan;Matthew S Loftus;Maria Thadani-Mulero;Ben P Levy.
Cancer Research (2011)
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Jason P. Gleghorn;Erica D. Pratt;Denise Denning;He Liu.
Lab on a Chip (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: